02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
20:40 , May 18, 2018 |  BioCentury  |  Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
02:28 , May 18, 2018 |  BC Week In Review  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
23:06 , May 14, 2018 |  BC Extra  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
23:37 , Dec 21, 2017 |  BC Extra  |  Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research , researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that...
19:51 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
18:17 , Sep 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); prostate cancer In vitro , cell culture and mouse studies identified two dihydropyrazolopyridine-based dual CREBBP / EP300 inhibitors that could help treat AML and prostate cancer. Chemical synthesis and in...
19:27 , Sep 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest EP300 inhibition with doxorubicin could help treat p53 -mutant colorectal cancer without the anemic and neutropenic side effects of doxorubicin alone. In a xenograft mouse model of p53-mutant colorectal...
23:09 , Aug 28, 2017 |  BC Week In Review  |  Clinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported preclinical data showing that prostate cancer candidate GNE-049 blocked expression of key proliferative genes and reduced tumor growth. In patient-derived xenograft mouse models of...